Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
01:29am, Friday, 23'rd Jan 2026
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
01:00am, Friday, 23'rd Jan 2026
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 wi
Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development
02:30pm, Thursday, 22'nd Jan 2026
Sanofi CEO Paul Hudson discusses the impact of AI in the pharmaceutical space during an interview with CNBC at the World Economic Forum in Davos on Thursday.
Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development
09:14am, Thursday, 22'nd Jan 2026
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss state of the pharmaceutical landscape, future of drug pricing, drug pipeline, impact of AI, and more.
Press Release: Myqorzo and Redemplo approved in China
01:00am, Thursday, 15'th Jan 2026
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to C
Sanofi sees softness in U.S. vaccine demand in near term
02:23pm, Wednesday, 14'th Jan 2026
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year due to misinformation and heightened scrutiny under the current administrat
Sanofi: Information concerning the total number of voting rights and shares - December 2025
12:30pm, Wednesday, 14'th Jan 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
10:20am, Tuesday, 13'th Jan 2026
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
07:38am, Tuesday, 13'th Jan 2026
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
05:34pm, Monday, 12'th Jan 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:26pm, Monday, 12'th Jan 2026
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
01:00am, Monday, 12'th Jan 2026
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
08:30am, Wednesday, 07'th Jan 2026
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.
Allspring Global Investments Holdings LLC Sells 10,390 Shares of Sanofi $SNY
03:18am, Wednesday, 07'th Jan 2026
Allspring Global Investments Holdings LLC reduced its stake in shares of Sanofi (NASDAQ: SNY) by 7.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
